Status:
COMPLETED
Effect of rEPO in FGF23 in ESRD Patients
Lead Sponsor:
University of Chile
Conditions:
Anemia
Chronic Kidney Diseases
Eligibility:
All Genders
18+ years
Brief Summary
Objective: To evaluate the effects of recombinant Erythropoietin (rEPO) in plasma levels of Fibroblast Growth Factor 23 (FGF23) in End-Stage Renal Disease (ESRD) patients in hemodialysis. Method: Pro...
Detailed Description
Experimental data has shown that recombinant erythropoietin (rEPO) increases plasma levels of Fibroblast Growth Factor 23 (FGF23) in murines, both health and with acute or chronic renal disease. Also,...
Eligibility Criteria
Inclusion
- End-Stage Renal Disease
- Requirements of Hemodialysis
- At least 6 months since initiation of hemodialysis
Exclusion
- Pregnancy
- Treatment with rhEPO or analogs during the previous 6 months or earlier
Key Trial Info
Start Date :
August 15 2017
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
October 20 2019
Estimated Enrollment :
60 Patients enrolled
Trial Details
Trial ID
NCT03803514
Start Date
August 15 2017
End Date
October 20 2019
Last Update
May 27 2020
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Hospital Clinico Universidad de Chile
Santiago, Chile